Whether the lowered IC50 from pre-irradiation render ABT-199 clinically effective remains to be tested, but the inhibition of multiple members of the Bcl-2 family will likely be needed to further reduce drug concentration and to address the diverse STS subtypes and tumour heterogeneity. Here, BCL2 is linked to neoplasm.